Navigation Links
Omnicare Clinical Research Acquired by Nautic Partners, LLC
Date:4/28/2011

KING OF PRUSSIA, Pa., April 28, 2011 /PRNewswire/ -- Omnicare Clinical Research (CR), a leading global, full-service contract research organization (CRO), announced today that it has been acquired by Nautic Partners, LLC, a private equity firm based in Providence, R.I. The signing of the deal not only makes official the separation of Omnicare CR from former parent company, Omnicare, Inc., it achieves the company's most visible step in a comprehensive two-year plan to accelerate Omnicare CR into the future.

With over 25 years of quality service, Omnicare CR has established its own strategic business-unit model to best serve the most complex trials. Over the last five years, Omnicare CR has successfully completed over 1,500 studies worldwide with more than 337,000 participating patients. Now, as the CRO takes this next step forward, added support from Nautic will allow Omnicare CR to meet customer needs even more quickly.

"Our new affiliation with Nautic is very exciting for all of us at Omnicare CR. This marks a new era for our business that will provide us the ability to more efficiently make vital, strategic decisions, placing us in control of our own destiny," said Dr. James M. Pusey, president & CEO of Omnicare CR. "The group in the best position to benefit from this reorganization is our current and future customer base. With our renewed strength, Omnicare CR will be able to deliver an even higher level of customer service while maintaining the teams currently in place who support our customers on a day-to-day basis."

According to Pusey, the affiliation with Nautic was the best possible partnership for the company. "The interest in Omnicare CR has been intense and our new partnership with Nautic gives us the opportunity to further specialize our business model, invest in the company's future and grow our high-quality organization."

Nautic's managing director, Chris Crosby, led the deal with Omnicare CR'
'/>"/>

SOURCE Omnicare Clinical Research
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
2. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
3. Tissue Genesis Begins FDA-Approved Clinical Trial
4. ClearCanvas Releases First Commercial Version of Popular Clinical Radiology Workstation; PACS and RIS to Follow
5. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
6. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
7. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
8. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
9. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
10. Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression to be Presented at the American Psychiatric Association Annual Meeting
11. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the ... their 2nd generation cell therapy POD® design. The 2nd generation portfolio not only ... a new POD® design. , “G-CON first offered our miniPOD CT product ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)... -- Indivior PLC (LON: INDV) today announced that the New ... and received Priority Review by the U.S. Food and ... This naloxone nasal spray comes as a pre-filled device ... the nasal mucosa. 1 The device has been ... better equipped to help an opioid overdose victim. ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... ... in forensic DNA analysis, announced that company researchers have proven DNA evidence ... and access to DNA or a DNA database. Recognizing the need ... of forensics, Nucleix scientists have developed a novel assay termed "DNA authentication" ...
... , , ... plc (LSE: SHP, Nasdaq: SHPGY ), the global ... to the care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a ... across the country.* The first initiative, "RoADHD Trip," a ...
... MISSISSAUGA, ON, Aug. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: ... received a letter from the Listing Qualifications Department of ... regained compliance with Listing Rule 5550(a)(2). , We plan ... Panel ("the Panel") to review the NASDAQ,s determination of ...
Cached Biology Technology:Nucleix Researchers Discover DNA Evidence May Easily be Falsified: Company Develops New Detection Technology for Preventing Biological Identity Theft 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified: Company Develops New Detection Technology for Preventing Biological Identity Theft 3Nucleix Researchers Discover DNA Evidence May Easily be Falsified: Company Develops New Detection Technology for Preventing Biological Identity Theft 4Shire Initiates Two Adult ADHD Outreach Programs 2Shire Initiates Two Adult ADHD Outreach Programs 3Shire Initiates Two Adult ADHD Outreach Programs 4Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 2
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... HOLLYWOOD, Calif., Dec. 10, 2012  Medbox, Inc. (OTC Markets: ... trading volume of 54,468 shares and finishing the day ... On Friday, the company had announced formation ... The targeted market segments mentioned were: pharmaceutical packaging (prescription ...
... on children continue to become ever more apparent. A ... BMC Public Health shows that second hand ... pregnant significantly increase the risk of invasive meningococcal disease. ... bacterial meningitis, can also cause severe illness when bacteria, ...
... Researchers show that the global epidemic of Clostridium ... caused by the spread of two different but highly ... was previously thought. The spread and persistence of both ... a frontline antibiotic. Unlike many other healthcare-associated bacteria, ...
Cached Biology News:Medbox, Inc. Comments on Record Trading Day 2Medbox, Inc. Comments on Record Trading Day 3Second-hand smoke increases risk of invasive meningococcal disease in children 2Bugs without borders 2